



A conversation about specialty referrals at Cedars-Sinai.


Crossbeam Health is an early-stage clinical software company studying how primary care and specialty care collaborate. Before we propose anything, we want to understand the problem from your side.

Prepared for Cedars-Sinai | July 2026 | crossbeamhealth.com

FOR DISCUSSION




Nationally, the referral journey breaks quietly at every step.



The referral decision is made alone, under time pressure. Illustrative.

Measure	What national data shows	Source
Referral volume	100M+ ambulatory specialty referrals a year in the US; only about half are ever completed.	MedCity News, 2025
Specialist wait	31 days on average for a new-patient appointment across 15 major metros, up 48 percent since 2004.	AMN Healthcare survey of physician appointment wait times, 2025
Network leakage	45 percent of referral revenue from employed primary care physicians leaves the network.	Advisory Board, 2024
Clinician burden	206M in-basket messages at one large academic health system in 2024, up from 58M in 2017.	Journal of Arthroplasty, 2025

Published national figures, our synthesis of the literature. What we want from these meetings is your picture: where this holds at Cedars-Sinai, where it does not, and what the real numbers are.





Where referrals work today, and why that is hard to copy.

What clinicians describe	Inside a fully integrated system
About a one-week wait	Internal-medicine referrals at Kaiser Permanente land in roughly a week, against a 31-day national average.
Protected video consult slots	Specialists hold dedicated slots for quick video consults, so advice does not wait for clinic space.
A screener in every specialty	Each department has a specialist screener who reviews every PCP referral and approves, declines, or advises.
PCPs consult the screener directly	The screener either sends a plan back to the PCP or approves the referral, before the patient moves.
One connected network	Outpatient and inpatient run on one tightly connected system, so the loop rarely drops.

Crossbeam clinician interviews, July 2026: three Kaiser Permanente clinicians, relayed secondhand, so directional. Wait-time benchmark: AMN Healthcare, 2025. A benchmark, not an endorsement.

Why it works there. Kaiser is a fully integrated payer plus provider (UPMC is similar): the same organization pays for care and delivers it, so specialist time spent screening referrals pays for itself. Clinicians at standalone academic systems describe the opposite experience, long waits and little feedback, precisely because that integration is missing.

The question we want to explore with Cedars-Sinai: can software carry the screener's judgment to the referral decision moment inside a system that is not payer-integrated, without restructuring anything?

THE DIRECTION WE ARE EXPLORING

The hallway consult, rebuilt inside the EHR.



ADVISORY PANEL · WORKING PROTOTYPE · DEMO DATA

Meridian EHR · HYPERVIEW

ChartIn BasketScheduleOrdersRx

Search patients, orders...

Rivera, Ana MD · Internal Medicine

JD

Jane D.

58 y.o. Female

MRN ****1234

CODE STATUS

Full code

ALLERGIES

NKDA

PROBLEM LIST

Iron deficiency anemia

RISK

moderate

CARE TEAM

Dr. A. Rivera (PCP)

COVERAGE

BlueCross PPO

LAST VISIT

Today, 9:00 AM

Office Visit · Jane D. Encounter open

Referral decision pending

Chart ReviewNotesOrdersResults ReviewIn Basket

ASSESSMENT / PLAN

58-year-old female with iron deficiency anemia, ferritin 9 ng/mL, Hgb 10.8 g/dL, trending down over 6 months. Celiac serology negative. Colonoscopy 2023: normal to cecum, adequate prep. No overt GI bleeding, no NSAID use, menses ceased 2019.

CONSIDERING

Referral to Gastroenterology for evaluation of persistent iron deficiency; question of small bowel evaluation vs repeat lower endoscopy vs empiric iron optimization.

TODAY

Reviewed trends, counseled on iron therapy adherence, rechecked CBC and retic panel. Patient prefers to avoid another procedure if reasonable.

RECENT RESULTS

Ferritin	9 ng/mL (L)	Hemoglobin	10.8 g/dL (L)
MCV	76 fL (L)	TTG-IgA	Negative

ACTIVE MEDICATIONS

Ferrous sulfate 325 mg daily · Lisinopril 10 mg daily · Atorvastatin 20 mg nightly. No NSAIDs, no anticoagulants.

ILLUSTRATIVE CONCEPT · DEMO DATA, FICTIONAL PATIENT · FICTIONAL EHR, NO AFFILIATION

New order: Referral: GastroenterologyeConsult: GILabs

crossbeam

OPENED BY YOU · ADVISORY

PROTOCOL MATCH

Iron deficiency without overt bleeding, prior normal colonoscopy

Authored and versioned by this system's gastroenterology division. Last review May 2026. View evidence basis

CONTEXT IT USED

Ferritin 9, Hgb 10.8, microcytic, trending down Labs

Colonoscopy 2023: normal to cecum, adequate prep Endoscopy

Celiac serology negative; no nsais, no anticoagulants. Chart

Red flags: none triggered on screen Rules v3.2

CROSSBEAM'S READ

basis shown

this is the kind of judgment the GI division prefers to weigh in on before a full referral, so an eConsult is the recommended door. This is advisory: the clinician chooses,

YOUR OPTIONS

you decide, always

Manage in primary care

capsule study + iron protocol, orders pending

Send eConsult RECOMMENDED

question + context pre-assembled · typ. reply < 1 day

Refer, enhanced

GI preferred workup attached to the referral

Advisory only. Crossbeam never places orders, never blocks a referral, and shows the basis for every suggestion. Review before acting.

Three paths, one panel	What happens, and who decides
Manage in primary care	Specialty-authored workup and orders arrive ready for the PCP to review and sign.
Send an eConsult	Question and chart context are pre-assembled; a specialist answers asynchronously and the PCP acts.
Refer, enhanced	The referral leaves with the specialty's preferred workup attached, so the specialist sees a prepared patient.
HOW IT BEHAVES	
Advisory only	The clinician always decides. A full referral stays one click away.
Invited, not interruptive	Opened by choice at the decision moment. No pop-ups, no hard stops.
Inside existing workflow	Lives in the EHR and rides the messaging rails clinicians already use.

This is a direction, not a product. What we build should follow what we learn here, starting in one specialty chosen together from your own pain-point data, then expanding specialty by specialty.

WHAT WE WANT TO LEARN FROM YOU

Seven questions we hope you will answer candidly.

Question	Why we ask
THE PROBLEM, IN YOUR WORDS	
1 Where does the referral experience break down most often, and for whom?	Your picture, not ours.
2 Walk us through a recent complex referral, end to end.	The real process, not the process chart.
SEVERITY AND OWNERSHIP	
3 How often do referrals stall or leave the network, and what does each one cost?	Sizes the problem in revenue and access.
4 Who owns this problem today: clinical leadership, finance, or the board? And who feels it most day to day?	Different owners see different problems; the owner is who drives change.
5 What has Cedars-Sinai already tried or bought here, and how has it worked?	What we build must beat what exists.
PRIORITY AND SUCCESS	
6 Is fixing referral management a top priority this year, or a known issue you can live with?	Honest priority beats polite interest.
7 What would make this a clear win for your team, and what would make it not worth your time?	Your success criteria become our test.



Prefer to answer in writing?

cedars.crossbeamhealth.com


Five minutes, in your own words, whenever suits you. Your answers go directly to our team and are never shared or published.

"This is not actually a problem" is one of the most useful answers you can give us.

WHAT HAPPENS NEXT

Listen first. Then a problem statement we write together.

Working session	What we do together	What you get
1 • Find the owner	Time with your clinicians and teams, watching how referrals actually move, and finding whose problem this really is: clinical leadership, finance, or the board. No selling, no demos.	An accurate picture of the problem, in your words, with the right people in the room.
2 • Validate with your data	A written problem statement brought back for correction, and the single most painful specialty identified from your own referral data.	A veto over our understanding, early, and evidence in your numbers.
3 • Co-design the model	If the problem holds, we shape the commercial structure and a focused pilot together, success criteria agreed before anything starts. How does Cedars-Sinai typically structure arrangements like this? That question is yours to answer.	A structure that makes sense for everyone. No open-ended pilots.



The hallway we are trying to rebuild. Illustrative.



Share your answers with us.
Scan, or visit cedars.crossbeamhealth.com.
Everything you tell us stays with our team.

We would rather hear a clear no early than run a polite pilot that goes nowhere.
Tell us where we are wrong; that is the most useful thing this meeting can produce.